Chantix, ED drug Web sites, drive most consumer Rx requests: study

Share this article:

Web sites for Pfizer's smoking cessation drug Chantix, erectile dysfunction drugs Cialis, marketed by Lilly and Pfizer's Viagra were the top three online branded pharma product portals driving offline consumer prescription requests, a new study shows.

The product site rankings were based on an online consumer research study of 5,112 US adults conducted by market research firm Manahattan Research.

“Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site,” said Manhattan Research president Mark Bard in a statement. “Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views.”

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

      1.  Pfizer's Chantix
      2.  Lilly's Cialis
      3.  Pfizer's Viagra
      4.  Eisai and Ortho-McNeil's Aciphex
      5.  Sanofi-Aventis' Ambien CR
      6.  GlaxoSmithKline's Levitra
      7.  Novartis' Lamisil
      8.  Sepracor's Lunesta
      9.  GlaxoSmithKline's Wellbutrin XL
    10.  Ortho-McNeil's Ortho Evra

  -courtesy of Manhattan Research

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...